(Q38117110)

29 August 2017

title

Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis (English)

1 reference

29 August 2017

0 references

Jiwon Oh

1

1 reference

29 August 2017

Paul W O'Connor

series ordinal

2

1 reference

29 August 2017

publication date

1 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

27

1 reference

29 August 2017

issue

8

1 reference

29 August 2017

page(s)

591-609

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-013-0080-z

29 August 2017

exact match

0 references

cites work

Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

FTY720 modulates human oligodendrocyte progenitor process extension and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Tumefactive multiple sclerosis lesions under fingolimod treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Fingolimod and multiple sclerosis: four cautionary tales

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Mechanism of action for leflunomide in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Leflunomide-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Birth outcomes in women who have taken leflunomide during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Pregnancy outcome in women exposed to leflunomide before or during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0080-Z

Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis

21 January 2018

1 reference

12 December 2020

Severe relapses under fingolimod treatment prescribed after natalizumab

1 reference

12 December 2020

Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference

1 reference

12 December 2020

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

1 reference

12 December 2020

An update of teriflunomide for treatment of multiple sclerosis

1 reference

12 December 2020

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

1 reference

12 December 2020

Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE).

1 reference

12 December 2020

Leflunomide for treating rheumatoid arthritis

1 reference

12 December 2020

The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.

1 reference

12 December 2020

Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction

1 reference

12 December 2020

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

12 December 2020

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Inhibition of Protein Tyrosine Phosphorylation in T Cells by a Novel Immunosuppressive Agent, Leflunomide

1 reference

12 December 2020

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

12 December 2020

Influence of monomethylfumarate on monocytic cytokine formation--explanation for adverse and therapeutic effects in psoriasis?

1 reference

12 December 2020

Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production

1 reference

12 December 2020

Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child

1 reference

12 December 2020

Manufacturer's response to case reports of PML

1 reference

12 December 2020

10.1007/S40263-013-0080-Z

Identifiers

DOI

1 reference

29 August 2017

1 reference